Twin Lakes Capital Management’s Moderna MRNA Stock Holding History

Twin Lakes Capital Management’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$86.2K	Hold	1,231	–	–	0.03%	112
2026 Q1	$62.5K	Sell	1,231 -496	-29%	-$23.1K	0.03%	125
2025 Q4	$50.9K	Sell	1,727 -45	-3%	-$1.22K	0.02%	131
2025 Q3	$45.8K	Hold	1,772	–	–	0.02%	137
2025 Q2	$48.9K	Hold	1,772	–	–	0.03%	134
2025 Q1	$50.2K	Hold	1,772	–	–	0.03%	125
2024 Q4	$73.7K	Hold	1,772	–	–	0.05%	121
2024 Q3	$118K	Hold	1,772	–	–	0.08%	98
2024 Q2	$210K	Hold	1,772	–	–	0.14%	80
2024 Q1	$189K	Hold	1,772	–	–	0.13%	87
2023 Q4	$176K	Hold	1,772	–	–	0.12%	89
2023 Q3	$183K	Hold	1,772	–	–	0.13%	81
2023 Q2	$215K	Hold	1,772	–	–	0.15%	78
2023 Q1	$272K	Hold	1,772	–	–	0.2%	65
2022 Q4	$318K	Hold	1,772	–	–	0.25%	63
2022 Q3	$210K	Buy	+1,772	New	+$269K	0.17%	82
2022 Q2	–	Sell	-1,772	Closed	-$305K	–	231
2022 Q1	$305K	Hold	1,772	–	–	0.17%	78
2021 Q4	$450K	Hold	1,772	–	–	0.24%	62
2021 Q3	$682K	Sell	1,772 -506	-22%	-$187K	0.4%	47
2021 Q2	$535K	Hold	2,278	–	–	0.3%	54
2021 Q1	$298K	Sell	2,278 -297	-12%	-$43K	0.18%	67
2020 Q4	$269K	Buy	+2,575	New	+$261K	0.19%	69

Other funds holding MRNA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Twin Lakes Capital Management's MRNA Position: Q2 2026 in Review

Twin Lakes Capital Management held its Moderna (MRNA) position steady in Q2 2026 at 1,231 shares worth $86.2K. The position accounts for 0.03% of the portfolio, ranked #112.

Twin Lakes Capital Management first reported a position in MRNA in Q4 2020 and has held it in 22 quarters since. The position peaked at $682K in Q3 2021. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

Twin Lakes Capital Management held 1,231 shares of Moderna worth $86.2K as of Q2 2026.
Twin Lakes Capital Management left its Moderna share count unchanged in Q2 2026.
Moderna made up 0.03% of Twin Lakes Capital Management's portfolio in Q2 2026, its #112 holding.
Twin Lakes Capital Management first reported a position in Moderna in Q4 2020 and has held it in 22 quarters since.
Twin Lakes Capital Management's Moderna position peaked at $682K in Q3 2021.
782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Twin Lakes Capital Management's 13F filing for Q2 2026, filed 18 Aug 2026.